Dr. Prashanth N. Vallabhanath, MD
Ophthalmology (Ophthalmic Plastic and Reconstructive Surgery Physician)
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 852
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: University of Michigan Medical School
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmic Plastic and Reconstructive Surgery Physician primary
OR license MD22584 -
Ophthalmology Physician
OR license MD22584
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohsu Hospital and Clinics Portland, OR
Medical groups
- Eye Health Northwest PC (73 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 852
- Services billed
- 2,760
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient complete exam of visual system | 431 | 415 |
| Established patient office or other outpatient visit, 30-39 minutes | 325 | 287 |
| Exam of visual field with extended testing | 203 | 189 |
| Established patient office or other outpatient visit, 20-29 minutes | 163 | 148 |
| Imaging of optic nerve | 156 | 148 |
| Exam of visual field with limited testing | 108 | 106 |
| Imaging of retina | 70 | 66 |
| Removal of cataract with insertion of prosthetic lens | 54 | 31 |
| Measurement of corneal curvature and depth of eye | 49 | 30 |
| Removal of growth of eyelid | 37 | 37 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Portland, OR | 520 |
| Erythromycin (erythromycin base) Other prescribers in Portland, OR | 383 |
| Latanoprost Other prescribers in Portland, OR | 353 |
| Timolol Maleate Other prescribers in Portland, OR | 100 |
| Restasis (cyclosporine) Other prescribers in Portland, OR | 78 |
| Azithromycin Other prescribers in Portland, OR | 78 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Portland, OR | 54 |
| Brimonidine Tartrate Other prescribers in Portland, OR | 51 |
| Prednisolone Acetate Other prescribers in Portland, OR | 29 |
| Cyclosporine Other prescribers in Portland, OR | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 5 payments worth $226 in total to this clinician.
| Amgen Inc. | $226 |
|---|
| Food and Beverage | $226 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $66,931 in research payments for these studies, mostly to the institutions running them.
- Subcutaneous anti IL6R for treatment of patients with Thyroid Eye Disease
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.